Circulation. 2003;107:32-37
Published online before print November 25, 2002, doi: 10.1161/01.CIR.0000047060.60595.CC
Published online before print November 25, 2002, doi: 10.1161/01.CIR.0000047060.60595.CC
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:32.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation
A New Drug–Drug Interaction
From the Department of Anesthesiology (W.C.L., L.A.W., C.J.N., K.H., A.S.H., A.R.T.) and Division of Cardiology, Department of Internal Medicine (E.R.B.), University of Michigan, Ann Arbor; General Clinical Research Center, University of North Carolina at Chapel Hill (P.B.W.); Division of Thrombosis, Department of Chemistry, Indiana University South Bend (D.G.M.C., K.E.G.); and Department of Anesthesiology, VA Medical Center, Ann Arbor, Mich (L.A.W.).
Correspondence to Wei C. Lau, MD, Department of Anesthesiology, University of Michigan Health System, 1500 East Medical Center Dr, 1G323 University Hospital, Box 0048, Ann Arbor, MI 48109-0048. E-mail weiclau{at}umich.edu
Background— We observed that the prodrug clopidogrel was less effective in inhibiting platelet aggregation with coadministration of atorvastatin during point-of-care platelet function testing. Because atorvastatin is metabolized by cytochrome P450 (CYP) 3A4, we hypothesized that clopidogrel might be activated by CYP3A4.
Methods and Results— Platelet aggregation was measured in 44 patients undergoing coronary artery stent implantation treated with clopidogrel or clopidogrel plus pravastatin or atorvastatin, and in 27 volunteers treated with clopidogrel and either erythromycin or troleandomycin, CYP3A4 inhibitors, or rifampin, a CYP3A4 inducer. Atorvastatin, but not pravastatin, attenuated the antiplatelet activity of clopidogrel in a dose-dependent manner. Percent platelet aggregation was 34±23, 58±15 (P=0.027), 74±10 (P=0.002), and 89±7 (P=0.001) in the presence of clopidogrel and 0, 10, 20, and 40 mg of atorvastatin, respectively. Erythromycin attenuated platelet aggregation inhibition (55±12 versus 42±12% platelet aggregation; P=0.002), as did troleandomycin (78±18 versus 45±18% platelet aggregation; P<0.0003), whereas rifampin enhanced platelet aggregation inhibition (33±18 versus 56±20% platelet aggregation, P=0.001).
Conclusions— CYP3A4 activates clopidogrel. Atorvastatin, another CYP3A4 substrate, competitively inhibits this activation. Use of a statin not metabolized by CYP3A4 and point-of-care platelet function testing may be warranted in patients treated with clopidogrel.
Key Words: drugs • pharmacology • platelets • statins
This article has been cited by other articles:
 |
|
 |
|
  T. Geisler, C. Zurn, M. Paterok, K. Gohring-Frischholz, B. Bigalke, K. Stellos, P. Seizer, B. F. Kraemer, J. Dippon, A. E. May, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy Eur. Heart J., July 1, 2008; 29(13): 1635 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Alvarez Jr. For better or for worse: The future of antiplatelet therapy Am. J. Health Syst. Pharm., June 1, 2008; 65(11): 1017 - 1017. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Srinivasan and D Smith Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance Postgrad. Med. J., April 1, 2008; 84(990): 217 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gilard, B. Arnaud, J.-C. Cornily, G. Le Gal, K. Lacut, G. Le Calvez, J. Mansourati, D. Mottier, J.-F. Abgrall, and J. Boschat Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study J. Am. Coll. Cardiol., January 22, 2008; 51(3): 256 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Gurbel, W. C. Lau, and U. S. Tantry Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel J. Am. Coll. Cardiol., January 22, 2008; 51(3): 261 - 263. [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Harle Point-of-Care Platelet Function Testing Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 247 - 251. [Abstract] [PDF]
|
|
|
|
|
|
D. J. Angiolillo and F. Alfonso Clopidogrel Statin Interaction: Myth or Reality? J. Am. Coll. Cardiol., July 24, 2007; 50(4): 296 - 298. [Full Text] [PDF]
|
|
|
|
|
|
J. Saw, D. M. Brennan, S. R. Steinhubl, D. L. Bhatt, K.-H. Mak, K. Fox, E. J. Topol, and on behalf of the CHARISMA Investigators Lack of Evidence of a Clopidogrel Statin Interaction in the CHARISMA Trial J. Am. Coll. Cardiol., July 24, 2007; 50(4): 291 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jaffe and B. H. Strauss Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives J. Am. Coll. Cardiol., July 10, 2007; 50(2): 119 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Howard-Alpe, J. de Bono, L. Hudsmith, W. P. Orr, P. Foex, and J. W. Sear Coronary artery stents and non-cardiac surgery Br. J. Anaesth., May 1, 2007; 98(5): 560 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Ayalasomayajula, S. Vaidyanathan, C. Kemp, P. Prasad, A. Balch, and W. P. Dole Effect of Clopidogrel on the Steady-State Pharmacokinetics of Fluvastatin J. Clin. Pharmacol., May 1, 2007; 47(5): 613 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1505 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Piorkowski, S. Fischer, C. Stellbaum, M. Jaster, P. Martus, A. J. Morguet, H.-P. Schultheiss, and U. Rauch Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone: Is Sufficient Cholesterol-Lowering Enough to Inhibit Platelets? J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1035 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Burton, I. Burton, and G. J Pearson Clopidogrel-Precipitated Rhabdomyolysis in a Stable Heart Transplant Patient Ann. Pharmacother., January 1, 2007; 41(1): 133 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O'Donoghue and S. D. Wiviott Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All? Circulation, November 28, 2006; 114(22): e600 - e606. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ibanez, G. Vilahur, and J. J. Badimon Pharmacology of thienopyridines: rationale for dual pathway inhibition Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G3 - G9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bassand Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G35 - G37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Beitelshees and H. L. McLeod Clopidogrel pharmacogenetics: promising steps towards patient care? Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1681 - 1683. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, U. Cavallari, E. Trabetti, M. Sabate, R. Hernandez, R. Moreno, J. Escaned, et al. Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1895 - 1900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Suh, B.-K. Koo, S.-Y. Zhang, K.-W. Park, J.-Y. Cho, I.-J. Jang, D.-S. Lee, D.-W. Sohn, M.-M. Lee, and H.-S. Kim Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel Can. Med. Assoc. J., June 6, 2006; 174(12): 1715 - 1722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Turgeon, C. Pharand, and V. Michaud Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism Can. Med. Assoc. J., June 6, 2006; 174(12): 1729 - 1729. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. F. Rehmel, J. A. Eckstein, N. A. Farid, J. B. Heim, S. C. Kasper, A. Kurihara, S. A. Wrighton, and B. J. Ring INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 Drug Metab. Dispos., April 1, 2006; 34(4): 600 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Wang, D. L. Bhatt, and E. J. Topol Aspirin and clopidogrel resistance: an emerging clinical entity Eur. Heart J., March 2, 2006; 27(6): 647 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Almsherqi, C. Mclachlan, P. J. Mossop, and Y. Deng Combined pharmacologic treatment with clopidogrel and statin for patients with acute coronary syndrome: is there a survival advantage? Eur. Heart J., September 2, 2005; 26(18): 1932 - 1932. [Full Text] [PDF]
|
|
|
|
 |
|
 S J Walsh, M S Spence, D Crossman, and A A J Adgey Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond Heart, September 1, 2005; 91(9): 1135 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Frelinger III and A. D. Michelson Clopidogrel: Linking Evaluation of Platelet Response Variability to Mechanism of Action J. Am. Coll. Cardiol., August 16, 2005; 46(4): 646 - 647. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ziegler, M. Schillinger, M. Funk, K. Felber, M. Exner, W. Mlekusch, S. Sabeti, J. Amighi, E. Minar, M. Brunner, et al. Association of a Functional Polymorphism in the Clopidogrel Target Receptor Gene, P2Y12, and the Risk for Ischemic Cerebrovascular Events in Patients With Peripheral Artery Disease Stroke, July 1, 2005; 36(7): 1394 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Lim, F. A. Spencer, J. M. Gore, O. H. Dabbous, G. Agnelli, E. M. Kline-Rogers, D. DiBenedetto, K. A. Eagle, R. H. Mehta, and for the GRACE Investigators Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry Eur. Heart J., June 1, 2005; 26(11): 1063 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Geiger, L. Teichmann, R. Grossmann, B. Aktas, U. Steigerwald, U. Walter, and R. Schinzel Monitoring of Clopidogrel Action: Comparison of Methods Clin. Chem., June 1, 2005; 51(6): 957 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Bates, W. C. Lau, and B. E. Bleske Loading, Pretreatment, and Interindividual Variability Issues With Clopidogrel Dosing Circulation, May 24, 2005; 111(20): 2557 - 2559. [Full Text] [PDF]
|
|
|
|
|
|
W. Hochholzer, D. Trenk, D. Frundi, P. Blanke, B. Fischer, K. Andris, H.-P. Bestehorn, H. J. Buttner, and F.-J. Neumann Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention Circulation, May 24, 2005; 111(20): 2560 - 2564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Bates and W. C. Lau Controversies in Antiplatelet Therapy for Patients With Cardiovascular Disease Circulation, May 3, 2005; 111(17): e267 - e271. [Full Text] [PDF]
|
|
|
|
|
|
G. Patti, G. Colonna, V. Pasceri, L. L. Pepe, A. Montinaro, and G. Di Sciascio Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Circulation, April 26, 2005; 111(16): 2099 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Nguyen, J. G. Diodati, and C. Pharand Resistance to clopidogrel: A review of the evidence J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1157 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Page II, G. G. Miller, and J. Lindenfeld Drug Therapy in the Heart Transplant Recipient: Part IV: Drug-Drug Interactions Circulation, January 18, 2005; 111(2): 230 - 239. [Full Text] [PDF]
|
|
|
|
|
|
D Mukherjee, E Kline-Rogers, J Fang, K Munir, and K A Eagle Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome Heart, January 1, 2005; 91(1): 23 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Alfonso, A Suarez, D J Angiolillo, M Sabate, J Escaned, R Moreno, R Hernandez, C Banuelos, and C Macaya Findings of intravascular ultrasound during acute stent thrombosis Heart, December 1, 2004; 90(12): 1455 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Katori, F. Szlam, J. H. Levy, and K. A. Tanaka A Novel Method to Assess Platelet Inhibition by Eptifibatide with Thrombelastograph(R) Anesth. Analg., December 1, 2004; 99(6): 1794 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gorchakova, N. von Beckerath, M. Gawaz, A. Mocz, A. Joost, A. Schomig, and A. Kastrati Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting Eur. Heart J., November 1, 2004; 25(21): 1898 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, C. Banuelos, R. Hernandez-Antolin, J. Escaned, R. Moreno, F. Alfonso, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability Eur. Heart J., November 1, 2004; 25(21): 1903 - 1910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cattaneo Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 1980 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Schulman Antiplatelet Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, October 20, 2004; 292(15): 1875 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Serebruany, M. G. Midei, A. I. Malinin, B. R. Oshrine, D. R. Lowry, D. C. Sane, J.-F. Tanguay, S. R. Steinhubl, P. B. Berger, C. M. O'Connor, et al. Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study Arch Intern Med, October 11, 2004; 164(18): 2051 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lim, J. Cornelissen, T. Routledge, S. Kirtland, S. C. Charman, S. Bellm, H. Munday, O. Khan, I. Masood, and S. Large Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 432 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Vaughan and A. M. Gotto Jr Update on Statins: 2003 Circulation, August 17, 2004; 110(7): 886 - 892. [Full Text] [PDF]
|
|
|
|
|
|
W. C. Lau, D. G.M. Carville, E. R. Bates, J. V. Mitsios, A. I. Papathanasiou, F. I. Rodis, M. Elisaf, J. A. Goudevenos, and A. D. Tselepis Clinical Significance of the Atorvastatin-Clopidogrel Drug-Drug Interaction * Response Circulation, August 10, 2004; 110(6): e66 - e67. [Full Text] [PDF]
|
|
|
|
|
|
D. Williams, I. Ford, G. Hawksworth, J. V. Mitsios, A. I. Papathanasiou, F. I. Rodis, M. Elisaf, J. A. Goudevenos, and A. D. Tselepis Potential Statin-Clopidogrel Interaction Requires More Study * Response Circulation, August 10, 2004; 110(6): e68 - e68. [Full Text] [PDF]
|
|
|
|
|
|
M. L. Stadius Diminishing returns ...and too many choices ...the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention J. Am. Coll. Cardiol., July 7, 2004; 44(1): 25 - 27. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wiviott and E. M. Antman Clopidogrel Resistance: A New Chapter in a Fast-Moving Story Circulation, June 29, 2004; 109(25): 3064 - 3067. [Full Text] [PDF]
|
|
|
|
|
|
S. Bellosta, R. Paoletti, and A. Corsini Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions Circulation, June 15, 2004; 109(23_suppl_1): III-50 - III-57. [Abstract] [Full Text]
|
|
|
|
|
|
A. Chieffo, E. Bonizzoni, D. Orlic, G. Stankovic, R. Rogacka, F. Airoldi, G. W. Mikhail, M. Montorfano, I. Michev, M. Carlino, et al. Intraprocedural Stent Thrombosis During Implantation of Sirolimus-Eluting Stents Circulation, June 8, 2004; 109(22): 2732 - 2736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Xiao and P. Theroux Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1982 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Shore-Lesserson New anticoagulants and antiplatelet agents Can J Anesth, June 1, 2004; 51(suppl_1): R9 - R9. [Full Text] [PDF]
|
|
|
|